Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy

The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle...

Full description

Bibliographic Details
Main Authors: Isart Roca, Jordi Requena, Michael J. Edel, Ana Belén Alvarez-Palomo
Format: Article
Language:English
Published: MDPI AG 2015-01-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:http://www.mdpi.com/2077-0383/4/2/243
id doaj-08cfdce4ae524ec8b2bd5cfab3db86bb
record_format Article
spelling doaj-08cfdce4ae524ec8b2bd5cfab3db86bb2020-11-25T01:02:10ZengMDPI AGJournal of Clinical Medicine2077-03832015-01-014224325910.3390/jcm4020243jcm4020243Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement TherapyIsart Roca0Jordi Requena1Michael J. Edel2Ana Belén Alvarez-Palomo3Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, Barcelona, SpainControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, Barcelona, SpainControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, Barcelona, SpainControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, Barcelona, SpainThe use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle since they allow allogenic transplantation, can be produced in large quantities, and, as compared to adult myoblasts, present more embryonic-like features and more proliferative capacity in vitro, which indicates a potential for more self-renewal and regenerative capacity in vivo. Different approaches have been described to make myogenic progenitors either by gene overexpression or by directed differentiation through culture conditions, and several myopathies have already been modeled using iPSC-MP. However, even though results in animal models have shown improvement from previous work with isolated adult myoblasts, major challenges regarding host response have to be addressed and clinically relevant transplantation protocols are lacking. Despite these challenges we are closer than we think to bringing iPSC-MP towards clinical use for treating human muscle disease and sporting injuries.http://www.mdpi.com/2077-0383/4/2/243induced pluripotent stem cellsskeletal musclemuscular dystrophymyogenic progenitorsstem cell therapy
collection DOAJ
language English
format Article
sources DOAJ
author Isart Roca
Jordi Requena
Michael J. Edel
Ana Belén Alvarez-Palomo
spellingShingle Isart Roca
Jordi Requena
Michael J. Edel
Ana Belén Alvarez-Palomo
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
Journal of Clinical Medicine
induced pluripotent stem cells
skeletal muscle
muscular dystrophy
myogenic progenitors
stem cell therapy
author_facet Isart Roca
Jordi Requena
Michael J. Edel
Ana Belén Alvarez-Palomo
author_sort Isart Roca
title Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
title_short Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
title_full Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
title_fullStr Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
title_full_unstemmed Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
title_sort myogenic precursors from ips cells for skeletal muscle cell replacement therapy
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2015-01-01
description The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle since they allow allogenic transplantation, can be produced in large quantities, and, as compared to adult myoblasts, present more embryonic-like features and more proliferative capacity in vitro, which indicates a potential for more self-renewal and regenerative capacity in vivo. Different approaches have been described to make myogenic progenitors either by gene overexpression or by directed differentiation through culture conditions, and several myopathies have already been modeled using iPSC-MP. However, even though results in animal models have shown improvement from previous work with isolated adult myoblasts, major challenges regarding host response have to be addressed and clinically relevant transplantation protocols are lacking. Despite these challenges we are closer than we think to bringing iPSC-MP towards clinical use for treating human muscle disease and sporting injuries.
topic induced pluripotent stem cells
skeletal muscle
muscular dystrophy
myogenic progenitors
stem cell therapy
url http://www.mdpi.com/2077-0383/4/2/243
work_keys_str_mv AT isartroca myogenicprecursorsfromipscellsforskeletalmusclecellreplacementtherapy
AT jordirequena myogenicprecursorsfromipscellsforskeletalmusclecellreplacementtherapy
AT michaeljedel myogenicprecursorsfromipscellsforskeletalmusclecellreplacementtherapy
AT anabelenalvarezpalomo myogenicprecursorsfromipscellsforskeletalmusclecellreplacementtherapy
_version_ 1725206302232150016